戻る Agenda
Session 6: IMPD-Q Only Trials : Operational and Disclosure Aspects
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
Ruediger Pankow, DRSc
Clinical Trial Regulatory Consultant | CTIS SME, Independent Consultant, Germany
Session 6: IMPD-Q Only Trials : Operational and Disclosure Aspects
Speaker(s)
Opening: Why does IMPD-Q only application exists?
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
IMPD-Q Owner Experience
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
IMPD-Q Owner Experience
Raquel Vaquer Pérez
EU CTR implementation lead, Bristol-Myers Squibb, Belgium
Academia Perspective
Stéphanie Kromar
Senior Regulatory Affairs Manager, European Organisation for Research and Treatment of Cancer (EORTC) , Belgium
Member State Experience
Jan Willem Kleinovink
Scientific staff / Validation team lead / CTIS Support, Central Committee on Research Involving Human Subjects (CCMO), Netherlands
Contributing Panelist
Marianne Lunzer, DrMed
Assessor, Dept of Clinical Trials, Federal Office for Safety in Health Care, AGES, Austria